首页 >
法规速递
-
关于将ICP-723口崩片纳入《儿童抗肿瘤药物研发鼓励试点计划（星光计划）》试点项目的公示-2025/8/21
2025-08-22查看详情 > -
Document: Members of the Coordinating group of European network of paediatric research at the European Medicines Agency (Enpr-EMA)-2025/9/30
2025-10-08查看详情 > -
Page: CVMP recommendations on limited market classification and eligibility for authorisation under Article 23-2025/11/7
2025-11-10查看详情 > -
Document: Concept paper on the guideline revision on good pharmacogenomic practice-2025/12/8
2025-12-09查看详情 > -
Document: Briefing Document for Quality Innovation Group (QIG) 1-to-1 meeting-2026/1/15
2026-01-16查看详情 > -
国家药监局药审中心关于发布《研发期间安全性更新报告的问答文件》的通告（2026年第19号）-2026/2/24
2026-02-27查看详情 > -
Page: List of medicines under additional monitoring-2026/3/25
2026-03-26查看详情 > -
Document: New product information wording: extracts from PRAC recommendations on signals adopted at the 12-15 January 2026 PRAC-2026/4/29
2026-04-30查看详情 > -
Post-Complete Response Letter Clarification Teleconferences Between FDA and ANDA Applicants Under GDUFA Guidance for Industry (Final)-2022/10/5
2022-11-15查看详情 > -
Draft Guidance: Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs-2023/4/12
2023-04-13查看详情 >
